" class="no-js "lang="en-US"> Lumira Ventures - Medtech Alert
Wednesday, September 03, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Lumira Ventures | Pharmtech Focus

Lumira Ventures

About Lumira Ventures

Lumira Ventures

Lumira Ventures invests in transformative biopharmaceutical, medical device and digital health companies located in North America. We are engaged partners who support the management teams of companies we invest in to build products that have the potential to allow people to lead fundamentally healthier, longer and more productive lives.

Related Story

Fundraising

 Lumira Ventures Closes on US$255 Million of New Capital to Build Transformative Healthcare Companies | Pharmtech Focus

Lumira Ventures Closes on US$255 Million of New Capital to Build Transformative Healthcare Companies

July 26 2021

Lumira Ventures today announced a significant expansion of its capital base to support the founding […]